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Statement of Translational Relevance 
High-grade serous ovarian carcinoma (HGSOC) is the fifth leading cause of cancer death in the 
United States and Canada. The majority of HGSOC are diagnosed as late-stage, high-grade 
serous ovarian carcinomas, for which prognosis is generally poor and few targeted therapies 
exist. Significant research effort has suggested several molecularly distinct subtypes of 
HGSOC, yet no consensus in the field exists and computational methods to analyze high-
dimensional gene expression datasets differ across studies. Although subtypes have been 
shown to differ in overall survival, the lack of agreement on molecular subtype definition has 
been cited as a barrier to their investigation through clinical trial. In the present study, we 
perform an analysis of a large compendium of HGSOC transcriptomes in order to evaluate the 
concordance of computational methods and address the emerging consensus in the field. We 
develop a subtype classifier that represents the consensus of HGSOC subtypes, and show that 
many tumors are of intermediate or mixed subtype based on currently defined subtypes. These 
findings improve our understanding of the molecular basis of high-grade serous carcinoma, an 





Purpose: The majority of ovarian carcinomas are of high-grade serous histology, which is 
associated with poor prognosis. Surgery and chemotherapy are the mainstay of treatment, and 
molecular characterization is necessary to lead the way to targeted therapeutic options. To this 
end, various computational methods for gene expression-based subtyping of high-grade serous 
ovarian carcinoma (HGSOC) have been proposed, but their overlap and robustness remain 
unknown.  
Experimental Design: We assess three major subtype classifiers by meta-analysis of publicly 
available expression data, and assess statistical criteria of subtype robustness and classifier 
concordance. We develop a consensus classifier that represents the subtype classifications of 
tumors based on the consensus of multiple methods, and outputs a confidence score. Using our 
compendium of expression data, we examine the possibility that a subset of tumors are 
unclassifiable based on currently proposed subtypes.  
Results: HGSOC subtyping classifiers exhibit moderate pairwise concordance across our data 
compendium (58.9%-70.9%, p < 10-5) and are associated with overall survival in a meta-
analysis across datasets (p < 10-5). Current subtypes do not meet statistical criteria for 
robustness to re-clustering across multiple datasets (Prediction Strength < 0.6). A new subtype 
classifier is trained on concordantly classified samples to yield a consensus classification of 
patient tumors that correlates with patient age, survival, tumor purity, and lymphocyte infiltration.  
Conclusion: A new consensus ovarian subtype classifier represents the consensus of 
methods, and demonstrates the importance of classification approaches for cancer that do not 






Ovarian carcinoma is a genomically complex disease, for which the accurate characterization of 
molecular subtypes is difficult but is anticipated to improve treatment and clinical outcome(1). 
Substantial effort has been devoted to characterize molecularly distinct subtypes of high-grade 
serous ovarian carcinoma (HGSOC) (Table 1). Initial large-scale efforts to classify HGSOC of 
the ovary did not reveal any reproducible subtypes(2). Tothill et al(3) reported four distinct 
HGSOC subtypes: (i) an immunoreactive expression subtype associated with infiltration of 
immune cells, (ii) a low stromal expression subtype with high levels of circulating CA125, (iii) a 
poor prognosis subtype displaying strong stromal response, correlating with extensive 
desmoplasia, and (iv) a mesenchymal subtype with high expression of N/P-cadherins. The 
Cancer Genome Atlas (TCGA) project also identified four subtypes characterized by (i) 
chemokine expression in the immunoreactive subtype, (ii) proliferation marker expression in the 
proliferative subtype, (iii) ovarian tumor marker expression in the differentiated subtype, and (iv) 
expression of markers suggestive of increased stromal components in the mesenchymal 
subtype, but did not report  differences in patient survival(4). Further experimental 
characterization revealed an increased number of samples with infiltrating T lymphocytes for the 
immunoreactive subtype, whereas desmoplasia, associated with infiltrating stromal cells, was 
found more often for the mesenchymal subtype(5).  Konecny et al.(6), independently evaluated 
the TCGA subtypes and also reported the presence of the four transcriptional subtypes using a 
de novo clustering and classification method.  
 
However, robustness and clinical relevance of these subtypes remain controversial(7). The 
previous subtyping efforts have assessed prognostic significance in different patient cohorts, 
and have taken different approaches to validate these subtypes in independent datasets. A 
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recent review of HGSOC subtyping schemes highlighted the difficulty of comparing results of 
studies that used different subtyping algorithms, and that better general agreement on how 
molecular subtypes are defined would allow more widespread use of expression data in clinical 
trial design.(1) 
 
Assessing the generalizability of subtyping algorithms is challenging as true subtype 
classifications remain unknown. This challenge is evident in the lack of published validation of 
the proposed HGSOC subtypes. Subsequent efforts have performed de novo clustering of new 
datasets and noted similarity in the clusters identified, but they have not reported quantitative 
measures such as classification accuracy or rate of concordance with previously published 
algorithms(8). In this article, we address these limitations by re-implementing three major 
subtyping methods(3,5,9) and assess between-classifier concordance and across-dataset 
robustness in a widely used database containing 1,770 HGSOC tumors(10), whose curation 
and data consistency has been independently validated(11). We show that each pair of subtype 
classifiers are significantly concordant, and are virtually identical for tumors classified with high 
certainty. However, the subtypes do not meet established standards of robustness to re-
clustering(12) and only approximately one-third of tumors are classified concordantly by all three 
subtype classifiers. Using this core set of tumors concordantly classified by each method, we 
develop consensusOV, a consensus classifier that has high concordance with the three 
classifiers, therefore providing a standardized classification scheme for clinical applications. 
Materials and Methods 
Datasets 
 
Analysis was carried out on datasets from the curatedOvarianData compendium; details of 
curation and of grading systems used by individual studies are described elsewhere (10). 
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Datasets were additionally processed using  the MetaGxOvarian package(13) (Supplementary 
Information). Analysis was restricted to datasets featuring microarray-based whole-
transcriptome studies of at least 40 patients with late stage, high-grade, primary tumors of 
serous histology. This resulted in 15 microarray studies, providing data for 1,774 patients (Table 
2). Duplicated samples identified by the doppelgangR package were removed(14). Survival 
analysis was performed for 13 of these datasets, which included 1,581 patients with annotated 
time to death or last time of follow-up.  
 
Implementation of Subtype Classifiers 
 
Subtype classifiers were re-implemented in R(15) using original data as described by 
Konecny(6), Verhaak(5), and Helland(9). These classifiers are based on nearest-centroids(6), 
subtype-specific single-sample GSEA(5), and subtype-specific linear coefficients(9), 
respectively. Implementations were validated by reproducing a result from each of the original 





Subtype calls from all included datasets were combined to generate a single Kaplan-Meier plot 
for each subtyping algorithm (stratified by subtype). Hazard ratios for overall survival between 
subtypes was estimated by Cox proportional hazards, and statistical significance was assessed 
by log-rank test using the survcomp R package(16). Hazard ratios were calculated using the 
lowest-risk subtype as the baseline group, and stratification by dataset was performed for 






Prediction Strength(12) is defined as a measure of the similarity between pairwise co-
memberships of a validation dataset from class labels assigned by (1) a clustering algorithm 
and (2) a classification algorithm trained on a training dataset (Supplementary Figure 1). The 
quantity is an established measure of cluster robustness with the following interpretation: a 
value of 0 or below indicates poor concordance, and a value of 1 indicates perfect concordance 
between models specified from training and validation data. Tibshirani and Walther(12), and 
subsequent applications of Prediction Strength(17), have considered a value of at least 0.8 to 
be an evidence of robust clusters. Prediction Strength was computed as implemented in the 
genefu Bioconductor package(18).  
 
The tumors in each dataset were clustered de novo using our reproduced implementations of 
the algorithms of Konecny, TCGA/Verhaak, and Tothill (Supplemental File, Section 
‘Reproduction of Subtype Clustering Methods’). Each dataset was also classified using 
implementation of the originally published subtype classifiers. This produced two sets of subtype 





For each pair of classifiers, subtypes were mapped based on the observed concordance 
suggested in the original studies: Subtype C2 from Tothill corresponding to Immunoreactive in 
TCGA/Verhaak and C1_Immunoreactive-like in Konecny; C4 corresponding to Differentiated 
and C2_Differentiated-like; C5 corresponding to Proliferative and C3_Proliferative-like; and C1 
corresponding to Mesenchymal and C4_Mesenchymal-like. Statistical significance of pairwise 
concordance was assessed by Pearson’s Chi-squared test, and Cramer’s V was assessed to 
evaluate the strength of concordance. Two-way concordance was defined as the proportion of 
patients that were classified as the same mapped subtype across methods. Similarly, overall 
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three-way concordance was defined as the proportion of tumors sharing the same mapped 
subtype across all three classifiers. Subtype-specific three-way concordance was defined as the 
number of tumors concordantly classified as that subtype by all three classifiers, divided by the 
number of tumors classified to that subtype by at least one method. 
 
Filtering tumors by classification margin 
 
Each subtype classifier outputs for each patient a real-valued score for each subtype. Marginally 
classifiable tumors were identified based on the difference between the top two subtype scores, 
denoted as the ‘margin’ value. Thus, a higher margin indicates a more confident classification. 
For each pair of subtype classifiers, classification concordance was assessed on both the full 
dataset and considering only patients classified with margins above a user-defined cutoff. 
 
Building a consensus classifier  
 
The consensusOV classifier was implemented using a Random Forest classifier trained on 
concordantly-subtyped tumors across multiple datasets. The Random Forest method has 
previously been used for building a multi-class consensus classifier to resolve inconsistencies 
among published colorectal cancer subtyping schemes(19). In order to avoid normalizing 
expression values across datasets, binary gene pair vectors were used as feature space, as 
recently applied for breast cancer subtyping(20,21). To address differences in gene expression 
scales due to different experimental protocols, consensusOV first standardizes genes in each 
dataset to the same mean and variance, and computes binary gene pairs from standardized 
expression values. Since the feature size of this classifier increases quadratically with respect to 
the size of the original gene set, we used the smallest gene set of the original subtype 
classifiers (the gene set of Verhaak et al.(5)), which contains 100 gene symbols. The 
consensusOV classifier outputs the subtype classification and a real-valued margin score to 
discriminate between patients that are of well-defined or indeterminate subtype. Similarly to 
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Performance of the consensus classifier for identifying concordantly classified subtypes was 
assessed using leave-one-dataset-out cross-validation(22). Concordant subtypes were 
identified to train the Random Forest classifier using 14 of the 15 datasets, and subtype 
predictions were tested in the remaining left-out dataset. This process was repeated for all 15 
datasets. While predicting the samples in any given dataset, the training set was subsetted to 
contain only the concordant subtypes in other datasets. 
 
Correlation analysis with Histopathology and Tumor Purity 
 
Subtype calls from the Consensus Classifier were analysed for correlation with histopathology 
and tumor purity in the TCGA dataset. In order to best represent the most confident subtype 
calls, a default cutoff was used to include only the 25% of patients with the largest classification 
margins. Available histopathology variables included lymphocyte, monocyte, and neutrophil 
infiltration. Tumor purity was assessed using the ABSOLUTE algorithm(23), which estimates 
purity and ploidy from copy number and SNP allele frequency from SNP genotyping arrays 
(Synapse dataset syn3242754). Significance of associations were tested by one-way ANOVA 




All results are reproducible using R/Bioconductor(24) and knitr(25) with LaTeX output at 
overleaf.com/read/srvqbpxpqbyz. Output of this code is provided as Supplemental File 1. 
10 
 
Subtyping algorithms are provided by the open source consensusOV R package available from 
Bioconductor (http://bioconductor.org/packages/consensusOV). 
Results 
We performed a meta-analysis of three published subtyping algorithms for HGSOC(5,6,9) and 
developed a new consensus classifier to identify unambiguously classifiable tumors (Table 1). 
Each of these algorithms identified four distinct HGSOC subtypes with specific clinical and 
tumor pathology characteristics (Figure 1). We assessed the algorithms on a compendium of 15 
datasets including over 1,700 HGSOC patients (Table 2) with respect to concordance, 
robustness, and association to patient outcome. By modifying individual algorithms to discard 
tumors of intermediate subtype, we found that concordance between algorithms is greatly 
improved.   
 
 
Concordance of published classifiers 
 
We reimplemented three published HGSOC subtype classifiers(5,6,9) (Table 1) and  applied 
these methods to new datasets. We ensured correct implementation of classifiers by 
reproducing results from the original papers (Supplementary Information). When applied to 
independent datasets, pairwise concordance of the three methods was statistically significant (p 
< 10-5, Chi-square test; Figure 2A) with the highest agreement observed for Helland and 
Konecny subtyping schemes (70.9%), followed by Verhaak and Helland (67.4%) and Verhaak 
and Konecny (58.9%). Cramer’s V coefficients(26) indicated a strong association between 
subtypes as identified by the different algorithms (>0.5).  
 
Tumors of intermediate subtype 
 
The individual subtyping algorithms calculate numeric scores for each subtype, and assign each 
tumor to the subtype with the highest score. A tumor with a large difference or “margin” between 
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the highest and second highest scores can be considered distinctly classifiable, whereas a 
tumor with two nearly equal scores could be considered of intermediate subtype. We examined 
the effect of modifying the individual algorithms to prevent assignment of indeterminate cases at 
various thresholds. For each pair of subtype classifiers, we examined the classification 
concordance with increasing thresholds on the margins.  
 
For all pairs of subtype classifier, classification concordance increased as additional marginal 
cases are removed, approaching over 90% concordance once the majority of tumors are left 
unclassified (Figure 2B). Three-way concordance followed the same trend with lower overall 
concordance: a minimum of 23% for the proliferative subtype and maximum of 45% for the 
immunoreactive subtype when all tumors are classified. Restricting the concordance analysis to 
the top 50% of tumors by margin value resulted in an increased overlap between 35% 
(proliferative) and 65% (immunoreactive). At a strict threshold of where only 10% of tumors are 
classified, 88% of tumors overall are concordantly classified by all three published subtyping 
algorithms (Figure 2C). This large gain in concordance results from large reductions in both 
singleton calls - tumors assigned to one subtype by one algorithm, but not by the other two 
algorithms - and in 2-to-1 calls, tumors assigned to one subtype by two algorithms, but not by 
the third (Figure 2D). This indicates that tumors distinctly classifiable by a single algorithm are 
more likely to be concordantly classified by the other algorithms, and conversely, tumors that 





All proposed subtyping algorithms classified patients into groups that significantly differed in 
overall survival (Figure 3A, p < 10-5 for each subtyping algorithm, log-rank test). Comparing low-
risk to high-risk subtypes for each algorithm, the hazard ratios increase from approximately 1.5 
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as marginal cases are removed (Figure 3B), suggesting that marginal cases may contribute to 
the intermediate survival profiles between subtypes.  
 
Robustness of the Classifiers 
 
Robust molecular subtyping should be replicable in multiple datasets. We performed de novo 
clustering in 15 independent ovarian datasets using the authors’ original gene lists and 
clustering methods. We compared these de novo clusters to the labels from our implementation 
of the published classifiers to assess robustness using the Prediction Strength (PS) statistic(12). 
For PS estimation, we included validation datasets with at least 100 HGSOC tumors. Overall we 
observed low robustness for all classifiers, with PS values under 0.6 for the three algorithms 
across datasets (Supplementary Figure 2), none meeting the 0.8 threshold typically indicating 
robust classes(12,17).  
 
To assess whether low confidence predictions are driving the PS estimation, we re-computed 
the robustness of each algorithm set to classify varying fractions of the tumors with the highest 
margins. We used the largest dataset available, the TCGA dataset, as the validation set, and 
varied margin cutoffs of the Tothill and Konecny classifiers to require them to classify between 
25% and 100% of the cases. From 10 random clustering runs, we report the median PS for the 
dataset. Clustering was performed on the full TCGA dataset and tumors of low margin values 
were removed subsequent to clustering and after the classifier was fully defined, in order to 
avoid optimistically biasing the apparent strength of clusters. We observed that the robustness 
of each algorithm is substantially improved by preventing them tto classify ambiguous cases. 
The Tothill algorithm achieved almost perfect robustness (PS = 0.96) when allowed to leave 






To maximize concordance across classifiers, we developed consensusOV, a consensus 
subtyping scheme facilitating classification of tumors of well-defined subtypes (Figure 5). This 
classifier uses binary gene pairs(20,21) to support application across gene expression 
platforms. The consensusOV classifier exhibits overall pairwise concordance of 67 - 78% with 
each of the other three algorithms, when classifying all tumors; and 94% concordance with 
tumors that are concordantly classified by the other three algorithms (Figure 5A). The margins 
of consensusOV are higher for concordantly classified cases than for non-concordantly 
classified cases, and this difference in margins is greater than for any of the other three 
classifiers (Figure 6A). Accordingly, consensusOV was also most effective in identifying 
concordantly classified cases, although it was similar to the Konecny classifier in this respect 
(AUC = 0.76, Figure 6B). As expected, differences in survival of subsets identified by 
consensusOV are similar to those identified by previous classifiers. The highest risk subtypes 
are proliferative (HR=1.44, 95% CI: 1.07−1.94) and mesenchymal (HR=1.97, 95% CI: 
1.46−2.67) when removing 75% of indeterminate low-margin tumors, with similar hazard ratios 
for the concordant cases (Figure 5B).  
Discussion 
The existence of four distinct and concordant molecular subtypes of HGSOC has been reported 
in several studies of large patient cohorts(4–6,9), but also called into question by another 
effort(2) that could not identify subtypes, and by an independent validation effort that reported 
only two or three reproducible subtypes(27). Meanwhile, significant effort is being expended to 
translate these subtypes to clinical practice, for example to predict response to the angiogenesis 
inhibitor bevacizumab in the ICON7 trial(28,29). Our study pursues three major objectives: (1) 
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reproduction of published subtype classification algorithms as an open-source resource; (2) 
evaluation of the robustness and prognostic value of each proposed subtyping scheme in 
independent data; and (3) consolidation of proposed subtyping schemes into a consensus 
algorithm.  
 
We find that while the proposed 4-subtype classifications demonstrate significant concordance 
and association with patient survival, none are robust to re-training in new datasets. By 
modifying any of these algorithms to prevent classification of tumors of ambiguous subtype, 
robustness and concordance of subtyping algorithms improve dramatically. We propose a 
“consensus” classifier that can identify the most unambiguously classifiable tumors, although a 
continuous trade-off exists between classifying more tumors versus having greater confidence 
in those classified. 
 
Ambiguity in tumor classification might arise from a heterogeneous admixture of different 
subtypes, or from a more homogeneous composition of indeterminate subtype. This distinction 
has implications for the therapeutic value of the proposed subtypes. Lohr et al. estimated that 
90% of tumors in the TCGA HGSOC dataset are polyclonal(30) , and clonal spread of HGSOC 
has been directly inferred from single-nucleus sequencing(31). However, it remains unclear 
whether multiple clones in a tumor are consistently classifiable to the same subtype. If a tumor 
consists of multiple clones of different subtypes, then a subtype-specific therapy will likely lead 
to relapse as other clones survive and continue to grow. If this situation is common, even 
unambiguously classifiable tumors might be contaminated by small amounts of another subtype 
that could lead to relapse after subtype-specific therapy. This question could not be resolved by 
the current datasets, but may eventually be addressed by single-cell RNA sequencing(32) which 




Several findings stand out in the validation of published subtyping algorithms. First, although 
previous studies reported inconsistent findings on whether subtypes differ by patient survival, 
our analysis in independent data showed clear survival differences. The 5-year survival rate for 
patients with different subtypes ranged from as low as 20% to as high as 50%. Second, 
published algorithms do not meet previously defined standards of robustness in terms of 
Prediction Strength, a measure of consistency between subtype classifiers trained in 
independent datasets. Finally, the concordance of three algorithms, established independently 
by different research groups from different patient cohorts, is only moderate but can be greatly 
improved by modifying the original algorithms to allow them to leave ambiguous tumors 
unclassified. In their original forms, all-way concordance of the four defined classes occurs in 
23% to 45% of tumors. As the individual algorithms are modified so they are allowed to leave 
ambiguous cases unclassified, the minority of remaining tumors can be classified with over 90% 
concordance between the three algorithms. This is a novel finding of interest, because an 
alternate possibility was that classifiers trained on different datasets would suffer low 
concordance no matter how they treated uncertain tumors. This finding suggests a subset of 
tumors of “pure” subtype; unfortunately, such unambiguous cases account for as few as 25% of 
HGSOC tumors. This places important limitations on the potential for clinical application of 
HGSOC subtypes. The proposed alternative, consensusOV, identifies the consensus of 
published HGSOC subtype classifiers. By training on multiple datasets, using binary (pairwise 
greater-than or less-than) relationships between pairs of genes, and using a relatively small 
gene set, it is designed to identify robustly classifiable HGSOC tumors across gene expression 
platforms and datasets. 
 
Moving forward, general agreement on how molecular subgroups of ovarian cancer are defined 
would facilitate the use of expression data in clinical management. (33).  The present subgroups 
while prognostically important are not yet clinically meaningful. Much like other prognostic 
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factors such as age, ascites, and histology, they do not alter clinical management. However, a 
better understanding of the biology underlying the subgroups will provide a more rational 
targeted treatment of those patients (perhaps first in trial) such as seen in HRD tumors with 
PARP inhibitors. The use of algorithms that can classify the tumor of an individual patient, while 
allowing some tumors to remain unclassified, along with assessment of subtype robustness in 
independent datasets by Prediction Strength, would move the field closer to this goal.  
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Affymetrix HT HG-U133A 12833 
GSE17260(35) 43:43 22 (29) Agilent-012391 Whole HG Oligo 19596 
GSE14764(36) 41:41:13 (30) Affymetrix HG-U133A 12752 
GSE18520(37) 53:53:41 (21) Affymetrix HG-U133 Plus 2.0 20282 





59:59:36 (34) Affymetrix HG-U133A 12752 
GSE51088(40) 85:84:69 (44) Agilent-012097 Human 1A Microarray (V2) 
G4110B 
15299 





ABI HG Survey Microarray Version 2 16760 
E.MTAB.386(43) 128:128:73 
(30) 
Illumina humanRef-8 v2.0 beadchip 10572 
GSE32062(44) 129:129:60 
(40) 
Agilent-014850 Whole HG 4x44K G4112F 19596 
GSE9891(3) 142:140:72 
(29) 
Affymetrix HG-U133 Plus 2.0 20282 
GSE26712(45) 185:185:129 
(39) 
Affymetrix HG-U133A Array 12752 
GSE20565(46) 89 (0) Affymetrix HG-U133 Plus 2.0 20282 
GSE2109 79 (0) Affymetrix HG-U133Plus2 20282 
 
Table 2: Compendium of gene expression datasets. 15 whole-transcriptome studies with at 
least 40 patients with late stage, high-grade serous histology from the curatedOvarianData 
compendium consisting of 1,770 patients. 13 of these datasets provided 1,581 patients with 
survival data.  Sample size column proves the number of samples : number with survival data : 









Figure 1: Properties of Subtypes identified by Consensus Classifier. Subtype associations 
with patient age and overall survival were assessed across our compendium of microarray 
datasets; association with tumor purity and immune cell infiltration was assessed using the 
TCGA dataset. Tumor purity was estimated from genotyping data in TCGA; lymphocyte 
infiltration was based on pathology estimates from TCGA. Patient age (p < 0.001), overall 
survival (p < 0.005), and ABSOLUTE purity (p < 0.001) were statistically significant across 
subtypes. When compared to all other groups, the Immunoreactive subtype had elevated 
infiltration of lymphocytes (p < 0.05) and neutrophils (p < 0.10). Mean monocyte infiltration was 
less than 5% across all subtypes, and was excluded from this analysis. Classification was 
performed using default parameters, and mean values of each variable are shown.  
 
Figure 2: Concordance Analysis. (A) Contingency table showing concordance of subtypes 
while comparing the methods pairwise (B) Pairwise concordance between the methods versus 
percentage of the dataset with samples of lower subtype margins removed, (C) three-way 
overall concordance between the methods and that of the individual subtypes versus 
percentage removed, (D) The classification of patients by three published algorithms as a Venn 
diagram for each of the four subtypes. Each area shows percentages of patients when all 
patients are classified (below, in parentheses) and after refusing to classify 75% of the most 
marginally classified tumors by any of the three methods (above). Thus, the numbers on the top 
of the three-way intersection are the concordant tumors according to the three original 
algorithms. Bottom numbers indicate relatively unambiguous subtype predictions by all three 
algorithms and which are also concordant with the others.   
 
Figure 3: Survival Analysis. (A) Kaplan-Meier curves of subtypes of the 1581 patients with 
survival data under different methods. (B) Hazard ratios and 95% confidence intervals of the 
lowest-risk subtype (Konecny and Verhaak) or two subtypes (Helland) compared to the 
remaining subtypes.  
 
Figure 4: Robustness Analysis of published classifiers, by Prediction Strength. In each 
dataset, concordance was calculated between the published classifier and a classifier re-trained 
on the validation dataset. The TCGA dataset also classified using the published classifiers of 
Helland and Konecny (no re-training was done for the classifiers). The TCGA dataset was also 
clustered using the methods of Tothill and Konency (in red and blue respectively). Samples 
were removed from Prediction Strength calculations starting with the most ambiguous samples 
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(with the smallest difference between the top subtype prediction and runner-up subtype 
prediction); the x-axis shows the percent removed before computing prediction strength. Each 
algorithm improves in robustness when allowed to leave ambiguous samples, that it is less 
certain in its classification, unclassified. 
 
Figure 5: Concordance and Survival Stratification of consensusOV. (A) Contingency plots 
showing concordance of subtype classification between consensusOV and the classifiers of 
Helland, Verhaak, Konecny. The fourth (bottom-right) plot shows the concordance between the 
consensus classifier and the patients concordantly classified between the three classifiers. (B) 
Survival curves for the pooled dataset provided by consensusOV. Classification was performed 
using leave-one-dataset-out validation. For the bottom two figures, classification with 
consensusOV was performed with the default cutoff, in which 75% of patients with the lowest 
margin are not classified. 
 
Figure 6: Margin Analysis. (A) Boxplots indicating the margin values assigned by each 
classifier to concordant and discordant cases. All statistical tests were performed using the 
Wilcoxon rank-sum test. (B) ROC curve for assessing the ability of margin values to discriminate 
between concordant and discordant cases. 
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